Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Durvalumab + LY2510924|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 67||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|LY2510924||CXCR4 Inhibitor 15||LY2510924 is a selective CXCR4 antagonist that prevents SDF-1 binding, potentially resulting in decreased tumor cell migration (PMID: 25504752, PMID: 32219196).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Durvalumab + LY2510924||Phase I||Actionable||In a Phase I trial, the combination of Imfinzi (durvalumab) and LY2510924 demonstrated safety and resulted in stable disease in 44.4% (4/9) of patients with advanced solid tumors, including one patient demonstrating an unconfirmed partial response (PMID: 32219196; NCT02737072).||32219196|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02737072||Phase I||Durvalumab + LY2510924||A Study of LY2510924 and Durvalumab in Participants With Solid Tumors||Terminated||0|